Unusual clinical features of autoimmune thyroid Disease;Besondere manifestationsformen der autoimmunthyreopathie

Praxis

Volumn 91, Issue 27-28, 2002, Pages 1151-1160

  Fajfr, R ^a   Muller B ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Autoimmune thyroid disease; Graves disease; Hashimoto thyroiditis

Indexed keywords

AUTOANTIBODY; HLA DQ ANTIGEN; HLA DQ1 ANTIGEN; PEROXIDASE; THYROTROPIN RECEPTOR;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; BLOOD; CASE REPORT; FEMALE; GENETIC PREDISPOSITION; GENETICS; GRAVES DISEASE; HUMAN; IMMUNOLOGY; MIDDLE AGED; THYROID GLAND;

ADULT; AUTOANTIBODIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GRAVES DISEASE; HLA-DQ ANTIGENS; HUMANS; MIDDLE AGED; PEROXIDASE; RECEPTORS, THYROTROPIN; THYROID GLAND; THYROIDITIS, AUTOIMMUNE;

EID: 0037014360     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.91.27.1151     Document Type: Review

References (60)

1. Davies T.F. Editorial: Autoimmune thyroid disease genes come in many styles and colors. J Clin Endocrinol Metab. 1998; 83 (10): 3391-3393. (Pubitemid 28500860)
2. McKenzie J.M., Zakarija M. Antibodies in autoimmune thyroid disease. In: Braverman LE, Utiger RD eds. The Thyroid. Lippincott-Raven, Philadelphia. 1996;416-432.
3. Kriss J.P., Pleshakov U., Chien J.R. Isolation and identification of the longacting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxoedema. J. clin. Endocr. 24. 1005-1028 (1964).
4. Reinwein D Funktion der Schilddrüse In Oberdisse K Klein E, Reinwein D (Hrsg): Die Krankheiten der Schilddrüse 2 Aufl Thieme, Stuttgart 1980.
5. Zakarija M., McKenzie J.M., Munro D.S.: Immunoglobulin G inhibitor of thyroid- stimulating antibody is a cause of delay in the onset of neonatal Graves' disease. J. clin. Invest. 72. 1352-1356 (1983).
6. Endo K., Kasagi K., Konishi J., Ikekubo K., Okuno T., Takeda Y., Mori T., Troizuka K. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto' s Thyroiditis. J. clin. Endocr. 46. 734 (1978).
7. Bech K., Bliddal H., Sirsbaek-Nielsen K., Friis K. Production of non-stimulatory TSH receptor blocking immunoglobulins in Graves' disease after radioiodine administration. Clin. Endocr. 17. 395 (1982).
8. Drexhage H.A., Doniach D., Bottazzo G.F., Bitensky L. Detection and clinical significance of antibodies stimulating or blocking thyroid growth in disorders of the thyroid gland. In Williams ED (Hrsg.): Current endocrine concepts. S. 37. Holt-Saunders. London 1982.
9. Eber O., Langsteger W. Clinical aspects of autoimmune thyroid diseases. Acta Med Austriaca (Austria), 1994, 21 (1) p 1-7. (Pubitemid 24151600)
10. Kraiem Z., Lahat N., Glaser B., Baron E., Sadeh O., Sheinfeld M. Thyrotropin receptor blocking antibodies: Incidence, characterization and invitro synthesis. Clin Endocrinol 1987; 27: 409-421. (Pubitemid 17148596)
11. Mariotti S., Pinchera A.: Role of the immune system in the control of thyroid function, in Greer MA (ed): The Thyroid Gland (Comprehensive Endocrinology). New York, Raven Press, 1990, pp 147-219.
12. Schneidinger P.H., Joller-Jemelka H., Grob P.J. Schilddrü senantikörper und ihre diagnostische Bedeutung. Schweiz. med. Wschr. 115. 1536-1544 (1985).
13. Dayan C.M., Daniels G.H. Chronic autoimmune thyroiditis. N Engl J Med 1996; 335. 99-107. (Pubitemid 26240112)
14. Badenhoop K., Walfish P.G., Rau H., et al. Susceptibility and resistance alleles of HLA DQA1 and HLA DQB1 are shared in endocrine autoimmune disease. J Clin Endocrinol Metab 1995; 80: 2112-2117.
15. Schumm-Draeger P.M. Thyreoiditis. Internist 1998. 39: 594-595
16. Konishi J., Iida Y., Kasagi K. et al. Primary myxedema with thyrotropinbinding inhibitor immunoglobulins. Ann Intern Med 1985; 103: 26-31.
17. Konishi J., Kasagi K., Iida Y Thyroid stimulation blocking antibodies - an overview In Nagataki S, Mori T, Torizuka K, eds 80 YEars of Hashimoto disease Amsterdam: Elsevier SCIENCE 1993: 573-7.
18. Tamaki H., Amino N., Kimura M., Hidaka Y., Takeoka K., Miyai K. Low prevalence of thyrotropin receptor antibody in primary hypothyroidism in Japan. J Clin Endocrinol Metab 1990; 71:1382-1386
19. Takasu N., Yamada T., Takasu M. et al. Disappearance thyrotropinblocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis. N Eng J Med 1992; 326: 513-518
20. Wilson J.D., Foster D.W., Kronenberg H.M., Larsen PR Williams Textbook of Endocrinology; 9th Edition; 1998: 422.
21. Irvin W.J., Toft A.D., Lidgard G.P., Gray R.S., Setz J., Cameron E.D.H. Spectrum of thyroid function in patients remaining in remission after antithyroid drug therapy for thyrotoxicosis. Lancet 1977;2:179.
22. Wood L.C., Ingbar S.H. Hypothyroidism as a late sequela in patients with Graves' disease treated with antithyroid drugs. J Clin Invest 1979;64:1429-1436
23. Hirota Y., Tamai H., Hayashi Y., Matsubayashi S., Matsuzuka F., Kuma K. et al. Thyroid function and histology in forty-five patients with hyperthyroid Graves' disease in clinical remission more than ten years after thionamide drug treatment. J Clin Endocrinol Metab 1986;62:165.
24. Sugrue D., McEvoy M., Feely J., Drury M.I. Hyperthyroidism in the land of Graves: results of treatment by surgery, radio-iodine and carbimazole in 837 cases. Q J Med 1980; 49: 51-61. (Pubitemid 10039100)
25. Hedley A.J., Young R.E., Jones S.J., Alexander W.D., Bewsher P.D. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow- up of 434 patients. Clin Endocrinol (Oxf) 1989; 31: 209-218 (Pubitemid 19196416)
26. Tamai H., Hirota Y., Kasagi K., Matsubayashi S., Kuma K., Iida Y., Konishi J., et al. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment. J Clin Endocrinol Metab 1987;64:718-722. (Pubitemid 17044538)
27. Livolsi V.A. The Pathology of autoimmune thyroid disease: a review. Thyroid 1994;4:333-339.
28. Li M., Eastman C.J., Boyages S.C. Iodineinduced lymphocytic thyroiditis in the BB/W rat: early and late immune phenomena. Autoimmunity 1993:14:181-187. (Pubitemid 23184816)
29. Li M., Boyages S.C. Iodide-induced lymphocytic thyroiditis in the BB/W rat: evidence of direct toxic effects of iodide on thyroid subcellular structure. Autoimmunity 1994;18:31-40. (Pubitemid 24295270)
30. Allen E.M., Appel M.C., Braverman L.E. The effect of iodide ingestion on the development of spontaneous lymphocytic thyroiditis in the diabetes prone BB/W rat. Endocrinology 1986;118:1977-1981. (Pubitemid 16106799)
31. Lazarus J.H., Marchant B., Alexander W.D., Clark D.H. 35S-antithyroid drug concentration and organic binding of iodine in the human thyroid. Clin Endocrinol 1975;4:609.
32. Cooper D.S. Treatment of thyrotoxicosis. In: Braverman LE, Utiger RD eds. The Thyroid. Lippincott-Raven, Philadelphia. 1991;887-916.
33. Leech N.J., Dayan C.M. Controversies in the management of Graves' disease. Clin Endocrinol 1998;49:273-280. (Pubitemid 28448932)
34. Kuma K., Matsuzuka H., Tamai H. A patient with Graves' disease unresponsive to massive dose of propylthiouracil. Clin Endocrinol 1982;30:136-139.
35. Li H., Okuda J., Akamizu T., Mori T. A hyperthyroid patient with Graves' disease who was strongly resistant to methimazole: investigation on possible mechanisms of the resistance. Endocrine J 1995;42:697-704.
36. Okuno A., Yano K., Inyaku F., Suzuki Y., Sanae N., Kumai M., Naith Y. Pharmacokinetics of methimazole in children and adolescents wit Graves' disease. Acta Endocrinol 1987;115:112-118.
37. Solomon B., Glinoer D., Lagasse R., Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990;70:1518.
38. Bahn R.S., Heufelder A.E. Pathogenesis of Graves' ophthalmopathy. N Eng J Med 1993; 329: 1468-1475 (Pubitemid 23335894)
39. Bahn R.S., Garrity J.A., Gorman C.A. Clinical review 13: Diagnosis and management of Graves' opthalmopathy. J Clin Endocrinol Metab 1990; 71: 559-563
40. Heufelder A.E. 1995 Involvement of the orbital fibroblast and TSH receptor in the pathogenesis of Graves' ophthalmopathy. Thyroid 5:331-339.
41. Heufelder A.E., Spitzweg C.h. Pathogenese der immunogenen Hyperthyreose und endokrinen Orbitopathie. Internist 1998. 39: 599-606. (Pubitemid 28297987)
42. Stadlmayr W., Spitzweg C., Bichlmair A.M., Heufelder A.E. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema. Thyroid 1997; 7: 3-12. (Pubitemid 27132889)
43. .Jacobson D.H., Gorman C.A. Diagnosis and management of endocrine ophthalmopathy. Med Clin North Am 1984; 69:973-988 (Pubitemid 16231614)
44. Forrester J.V., Sutherland G.R., McDougall I.R. Dysthyroid opthalmopathy: orbital evaluation with B-scan ultrasonography. J Clin Endocrinol Metab 1977;45:221-224 (Pubitemid 8162805)
45. Werner S.C., Coleman D.J., Franzen L.A. Ultrasonographic evidence of a consistent orbital involvement in Graves' disease. N Engl J Med 1974;2901:447-450
46. Enzmann D., Marshal W.H. Jr, Rosenthal A.R., Kriss J.P. Computed tomography in Graves' ophthalmopathy. Radiology 1979;118:615-620
47. Weetman A.P., McGregor A.M. Autoimmune thyroid disease: Further developments in our understanding. Endocrine Reviews 1994;15:788-830.
48. Teng C.S., Yeo P.P. Ophthalmic Graves' disease: natural history and detailed thyroid function studies. Br Med J 1977;1:273-275 (Pubitemid 8021365)
49. Solomon D.H., Chopra I.J., Chopra U., Smith F.J. Identification of subgroups of euthyroid Graves' ophthalmopathy. N Engl J Med 1977;296:181-186 (Pubitemid 8031204)
50. Hall R., Kirkham K., Doniach D., el-Kabir D. Ophthalmic Graves' disease. Diagnosis and pathogenesis. Lancet 1970;1:375-378
51. Lawton N.F., Ekins R.P., Nabarro J.D.N. 1971 Failure of pituitary response to thyrotropin-releasing hormone in euthyroid Graves' disease. Lancet 2:14-16.
52. Franco P.S., Hershman J.M., Haigler D., Pittman J.A. 1973 Response to thyrotropin- releasing hormone compared with thyroid suppression tests in euthyroid Graves' disease. Metabolism 22:1357-1365.
53. Shimizu T., Shishiba Y. 1973 Normal serum triiodothyronine concentration and the lack of TSH response to TRH in patients with euthyroid Graves' disease. Endocrinol Jpn 20:527-528.
54. Kasagi K., Hatabu H., Tokuda Y., Iida Y., Endo K., Konishi J. 1988 Studies on thyrotropin receptor antibodies in patients with euthyroid Graves' disease. Clin Endocrinol 29:357-366.
55. Kashiwai T., Tada H., Asahi K., Hidaka Y., Tamaki H., Iwatani Y., Amino N. 1995 Significance of thyroid stimulating antibody and long term follow up in patients with euthyroid Graves' disease. Endocr J 42:405-412.
56. Feliciello A., Porcellini A., Ciullo I., Bonavolonta G., Avvedimento E.V., Fenzi G. 1993 Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet 342:337-338. (Pubitemid 23227563)
57. Major B.J., Cures A., Frauman A.G. 1997 The full length and splice variant thyrotropin receptor is expressed exclusively in skeletal muscle of extraocular origin: A link to the pathogenesis of Graves' opthalmopathy. Biochem Biophys Res Commun 230:493-496. (Pubitemid 27225560)
58. Kashiwai T., Tada H., Watanabe Y., Shimaoka Y., Yagoro A., Hidaka Y. et al. Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease. Thyroid 1998;8:881-885. (Pubitemid 28514179)
59. Kahaly G., Böckmann H., Beyer J., Bischoff S. Longterm observation of endocrine opthalmopathy and retrospective appraisal of therapeutic measures. J Endocr Invest 1990;13:287-292. (Pubitemid 20190448)
60. Wilson J.D., Foster D.W., Kronenberg H.M., Larsen PR Williams Textbook of Endocrinology; 9th Edition; 1998: 476.